Last reviewed · How we verify

NCT07036263

Effect of Oculomotor Therapy in Individuals With Convergence Insufficiency

Not yet recruiting NA Last updated 25 June 2025
What this trial tests

NA trial testing Oculomotor therapy in Convergence Insufficiency in 70 participants. Not yet recruiting.

Timeline
1 August 2025
Primary endpoint
30 November 2025
30 December 2025

Quick facts

Lead sponsorUniversity of Nove de Julho
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment70
Start date1 August 2025
Primary completion30 November 2025
Estimated completion30 December 2025

Drugs / interventions tested

Conditions studied

Sponsor

University of Nove de Julho

Who can join

Adults 18 to 60, any sex, with Convergence Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the effect of oculomotor therapy in individuals with ocular convergence insufficiency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Oculomotor therapy

Trials testing the same drug.

Other recruiting trials for Convergence Insufficiency

Currently open trials in the same condition.

Other University of Nove de Julho trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07036263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing